Our Services

Blood and Marrow Transplantation Research

The physicians at Children’s Hospital of Pittsburgh of UPMC's Blood and Marrow Transplantation (BMT) program are constantly striving to improve cellular therapies for treatment of childhood cancer and blood diseases. A number of studies are under way looking at treatment methods that will make marrow and cord blood transplants kinder, gentler, and safer. Their ultimate goals are to reduce the complication rate and improve quality of life for children undergoing this procedure.

Meet the Researchers

Paul Szabolcs, MD
Chief, Division of Blood and Marrow Transplantation
Rakesh K. Goyal, MD, Blood and Marrow Transplant Director
Clinical Director, Division of Blood and Marrow Transplantation
Randy Windreich, MD Randy Windreich, MD
Mark Vander Lugt, MD Mark Vander Lugt, MD

Faculty Research Interests

Paul Szabolcs, MD

  • Laboratory Research: Immune Reconstitution, Tolerance and Alloreacivity,  Cellular Immunotherapy 
  • Clinical Research: Crohn’s Disease and other autoimmune diseases, Krabbe Disease and other Leukodystrophies, MPS Syndromes, High risk leukemias

Rakesh K. Goyal, MD 

Dr. Goyal's clinical research is focused on understanding the relationship between individual genetic variability and graft-versus-host disease (GVHD) and other posttransplant outcomes. Researchers such as Dr. Goyal have learned that individual variation in immune-response genes influences a child’s outcome after transplantation. They are investigating this theory by studying donors and recipients of unrelated donor transplantation.

Other Research Interests

  • Evidence-based medicine
  • Clinical pharmacology of immunosuppression
  • Novel regimens in reducing toxicities of transplant
  • Electronic Health Record use optimization

Randy M. Windreich, MD

Dr. Randy Windreich's clinical research is focused on individualizing therapy, to move away from the "one size fits all" approach in order to tailor therapies to a person's own individual metabolic needs. His aim in doing so is to optimize dosing for medications used for graft-versus-host disease prevention and treatment in addition to those used for antifungal prophylaxis.

Mark T. Vander Lugt, MD

Dr. Vander Lugt’s research has focused on the discovery and validation of biomarkers of acute graft-versus-host disease. Using a proteomic analysis of plasma from patients undergoing bone marrow transplantation, he was involved in the discovery of a new biomarker for the diagnosis of gastrointestinal graft-versus-host disease, and also in the discovery of a biomarker, ST2, that can predict which patients will respond to graft-versus-host disease therapy and subsequent non-relapse mortality following transplantation. Currently, his work is focused on transplantation for non-malignant conditions.  

Check out our clinical studies.

Last Update
October 18, 2012
  • Increase/Decrease Text Size
  • Print This Page
Last Update
October 18, 2012